Caloxin 1C2

CAT:
804-HY-P10655-01
Size:
1 mg

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Caloxin 1C2 - image 1

Caloxin 1C2

  • Description :

    Caloxin 1C2 is a specific PMCA (plasma-membrane Ca2+-ATPases) inhibitor. Caloxin 1C2 is selective for PMCA4 over PMCA1, 2 and 3. The Ki values of Caloxin 1C2 are 2.3 μM for PMCA4 and 21 μM for PMCA1. Caloxin 1C2 dose not cause any significant effects on total Ca2+ transfer. Caloxin 1C2 affects coronary contractility[1][2].
  • UNSPSC :

    12352209
  • Target :

    Calcium Channel; Proton Pump
  • Type :

    Peptides
  • Related Pathways :

    Membrane Transporter/Ion Channel; Neuronal Signaling
  • Applications :

    Neuroscience-Neuromodulation
  • Field of Research :

    Cardiovascular Disease
  • Assay Protocol :

    https://www.medchemexpress.com/caloxin-1c2.html
  • Purity :

    99.47
  • Solubility :

    DMSO : 100 mg/mL (ultrasonic)
  • Smiles :

    O=C(N[C@@H](C)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CO)C(N[C@@H](CCC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(NCC(NCC(NCC(N[C@@H](CO)C(N[C@@H](CCCCN)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]([C@H](O)C)N
  • Molecular Formula :

    C80H134N26O24
  • Molecular Weight :

    1844.08
  • References & Citations :

    [1]Sillanpää JK, et al. Calcium transfer across the outer mantle epithelium in the Pacific oyster, Crassostrea gigas. Proc Biol Sci. 2018 Nov 14;285 (1891) :20181676.|[2]Pande J, et al. Functional effects of caloxin 1c2, a novel engineered selective inhibitor of plasma membrane Ca (2+) -pump isoform 4, on coronary artery. J Cell Mol Med. 2008 Jun;12 (3) :1049-60.
  • Shipping Conditions :

    Blue Ice
  • Storage Conditions :

    -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
  • Scientific Category :

    Peptides
  • Clinical Information :

    No Development Reported